TNF and lung disorder: Twelve csDMARDs were modified (10 because of inefficacy and 2 because of adverse effects), and several bDMARDs were suspended for the following reasons: anti-TNF owing to progression of lung disease, 5 patients; tocilizumab owing to adverse effects, 2 patients; abatacept owing to ineffective treatment of joint involvement, 2 patients; and rituximab owing to adverse effects, 2 patients.